Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCeladon Pharmaceuticals Regulatory News (CEL)

  • This share is currently suspended. It was suspended at a price of 13.40
  • There is currently no data for CEL

Holding(s) in Company

7 Jan 2008 16:37

Celsis International PLC07 January 2008 TR-1: NOTIFICATION OF MAJOR INTERESTS IN SHARES (1). Identity of the issuer or the underlying issuer of existing shares to whichvoting rights are attached: CELSIS INTERNATIONAL PLC 2. Reason for the notification (please state Yes/No): ( ) An acquisition or disposal of voting rights: X An acquisition or disposal of financial instruments which may result in the acquisition of shares already issued to which voting rights are attached: An event changing the breakdown of voting rights: Other (please specify) : 3. Full name of person(s) subject to the notification obligation: BARCLAYS GLOBAL INVESTORS 4. Full name of shareholder(s) (if different from 3.): BARCLAYS GLOBAL INVESTORS LTD 5. Date of the transaction and date on which the threshold is crossed or reachedif different): 20-Dec-07 6. Date on which issuer notified: 24-Dec-07 7. Threshold(s) that is/are crossed or reached: 0% to 5% 8. Notified details: A: Voting rights attached to shares Class/type of shares Situation previous to if possible using the the Triggering ISIN CODE transaction Number of shares Number of voting Rights GB00B0CD5F69 0 0 Resulting situation after the triggering transaction Class/type of shares Number of shares Number of voting rights % of voting rights if possible using the ISIN CODE Direct Indirect Direct Indirect GB00B0CD5F69 1,190,770 0 1,190,770 0.00 5.39 B: Financial Instruments Resulting situation after the triggering transaction Type of Expiration Date Exercise/Conversion Number of voting % of voting financial Period/ Date rights that may be rights instrument acquired if the instrument is exercised/ converted. Total (A+B)Number of voting rights % of voting rights 1,190,770 5.39 9. Chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held, if applicable: BARCLAYS GLOBAL INVESTORS LTD Proxy Voting: 10. Name of the proxy holder: 11. Number of voting rights proxy holder will cease to hold: 12. Date on which proxy holder will cease to hold voting rights: 13. Additional information: 14. Contact name: GEOFF SMITH 15. Contact telephone number: 020 7116 2913 This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
8th Aug 20257:00 amRNSCancellation - Celadon Pharmaceuticals Plc
5th Aug 20256:00 pmRNSCeladon Pharmaceuticals
28th Jul 20254:10 pmRNSResult of General Meeting
2nd Jul 20257:00 amRNSProposed Cancellation
1st Jul 202511:48 amRNSFunding Update
1st Jul 20258:20 amRNSResult of AGM
1st Jul 20257:30 amRNSSuspension - Celadon Pharmaceuticals Plc
30th Jun 20257:00 amRNSFunding and Operational Update, Delay in Results
11th Jun 20257:00 amRNSNew Committed Credit Facility
6th Jun 20253:55 pmRNSFunding Update, Notice of AGM
30th May 20256:07 pmRNSFunding Update
30th Apr 20257:00 amRNSFunding Update
8th Apr 20253:05 pmRNSTermination of Facility
31st Mar 20253:15 pmRNSFunding Update
24th Mar 20257:00 amRNSBoard Changes and De-Listing Proposal
19th Mar 20257:00 amRNSFunding Update
26th Feb 20251:00 pmRNSNew Committed Credit Facility
12th Feb 20257:00 amRNSFinance Update
31st Jan 20257:00 amRNSFinance Update
16th Jan 20257:00 amRNSUpdate on Strategic Collaboration
2nd Jan 20257:00 amRNSFunding Update
20th Dec 20247:00 amRNSFinance Update
6th Dec 20247:00 amRNSReceipt of Subscription Proceeds
18th Nov 20247:00 amRNSUpdate on Financial Position
2nd Oct 20247:00 amRNSNew Sales Contract with a Healthcare Company
30th Sep 20247:05 amRNSDeparture of Chief Financial Officer
30th Sep 20247:00 amRNSInterim Results
17th Sep 20249:28 amRNSAdmission of Shares and Total Voting Rights
11th Sep 20247:05 amRNSEquity Fundraise and Update on Financial Position
11th Sep 20247:00 amRNSStrategic collaboration with Valeos
23rd Aug 20247:00 amRNSUpdate on Financial Position
12th Aug 20247:00 amRNSUpdate on Operations and Financial Position
16th Jul 20247:00 amRNSSuccessful Completion of Eighth Harvest of 2024
15th Jul 20241:58 pmRNSThird Admission of Shares
28th Jun 20247:00 amRNSResult of AGM
7th Jun 20247:00 amRNSSecond Admission of Shares
3rd Jun 20245:45 pmRNSPublication of Annual Report & Notice of AGM
23rd May 20247:00 amRNSSupply of Products to New US Customer
15th May 20242:45 pmRNSExercise of Share Options and Total Voting Rights
14th May 20247:00 amRNSFinal Results
10th May 20247:00 amRNSFundraise, RCF Extension, Termination of CLN & TVR
7th Mar 20247:00 amRNSEarly Economic Analysis of Feasibility Study Data
14th Dec 20237:00 amRNSProduct Supplied to First Two Sales Contracts
12th Dec 20232:00 pmRNSFundraise, Update on Future CLN Financing & TVR
16th Nov 20237:00 amRNSNew European Sales Contract
13th Oct 20237:00 amRNSFundraise, CLN Issue, Joint Broker Appointed & TVR
28th Sep 20237:00 amRNSInterim Results
18th Sep 20237:00 amRNSNotice of Results and Investor Presentation
5th Sep 20237:00 amRNSNew Sales Contract with UK Pharmaceutical Company
1st Aug 20237:00 amRNSApproval to roll-out chronic pain clinical trial

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.